LaNeo

PharmAla Biotech Holdings Inc. (OTC:MDXXF) has announced that it will supply its Good Manufacturing Practice LaNeo MDMA for a clinical trial at Mt. Sinai Health System. The biotechnology company specializes in the research, development, and production of MDMA and novel MDXX-class molecules. "We're...

PharmAla Biotech Holdings Inc. (OTC:MDXXF), a Canadian company specializing in MDMA research and development, announced its selection as a supplier for a clinical trial at the University of Texas, San Antonio. The trial will focus on testing a novel dosage form of PharmAla's proprietary LaNeo MDMA...

PharmAla Biotech Holdings Inc, the biotech company producing MDXX class molecules has released a large-scale batch of its proprietary MDMA API, “Laneo,” becoming the first publicly-traded venture to produce the drug within Good Manufacturing Processes (GMP) in such a major...